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Abstract 
Introduction: The current therapeutic strategies are based on the discovery and developing of 
multifunctional drug candidates able to interact with various disease related targets. Drugs that 
have the ability to scavenge reactive oxygen species (ROS), beyond their main therapeutic action, 
may prevent the oxidative damage of biomolecules. Therefore, analytical approaches that monitor 
in a continuous mode the ability of drugs to counteract peroxidation of physiologically relevant 
biotargets are required. 
Objectives: A microplate spectrophotometric assay is tested and proposed to evaluate the ability 
of selected cardiovascular drugs to prevent protein peroxidation.  
Methods: The scavenging capacity of several drugs was tested and compared with two 
endogenous antioxidants (taurine and reduced glutathione). The studied drugs included a 
angiotensin-converting enzyme inhibitor (enalapril), several β-blockers (atenolol, labetalol and 
propranolol) and two statins (pravastatin and fluvastatin). Myoglobin, which is a heme protein, 
and peroxyl radicals generated from thermolysis of 2,2'-azo-bis(2-amidinopropane) 
dihydrochloride at 37 °C, pH 7.4 were selected as protein model and oxidative species, 
respectively. Myoglobin peroxidation was continuously monitored by the absorbance decrease at 
409 nm and the ability of drugs to counteract protein oxidation was determined by the calculation 
of the area under the curve upon the myoglobin oxidation.  
Results and Conclusions: Fluvastatin (AUC50 = 12.5 ± 1.2 µM) and enalapril (AUC50 = 15.2 ± 
1.8 µM) showed high ability to prevent myoglobin peroxidation, providing even better efficiency 
than endogenous antioxidants such as reduced glutathione. Moreover, labetalol, enalapril and 
fluvastatin prevent the autooxidation of myoglobin, while glutathione showed a pro-oxidant effect. 
Keywords: Myoglobin; Peroxyl radical; Protein oxidation; Microplate; Statins; β-Blockers.  
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Resumo 
Introdução: As estratégias terapêuticas atuais residem na descoberta e desenvolvimento de 
fármacos multifuncionais que sejam capazes de intervir em diferentes alvos terapêuticos. Os 
fármacos que possuem a capacidade de sequestrar espécies reativas do oxigénio (ERO), para além 
do seu principal efeito terapêutico, podem dessa forma prevenir o dano oxidativo das 
biomoléculas. Neste contexto, torna-se necessário dispor de metodologias que monitorizem em 
modo contínuo a capacidade dos fármacos impedirem a peroxidação dos alvos biológicos. 
Objetivos: Testar e propor um método espetrofotométrico em microplaca para avaliar a 
capacidade de fármacos usados na área cardiovascular para prevenirem a peroxidação proteica.  
Métodos: A capacidade antioxidante de vários fármacos foi testada e comparada com a de dois 
antioxidantes endógenos (taurina e glutationa reduzida). Os fármacos estudados incluíram um 
inibidor da enzima de conversão da angiotensina (enalapril), vários β–bloqueadores (atenolol, 
labetalol, propanolol) e duas estatinas (pravastatina e fluvastatina). Como proteína modelo foi 
selecionada a mioglobina, proteína heme, enquanto que os radicais peroxilo foram gerados a partir 
da termólise a 37ºC, pH 7,4 do 2,2'-azo-bis(2-amidinopropano) dicloridrato como espécie 
oxidativa. A peroxidação da mioglobina foi monitorizada continuamente pelo decréscimo de 
absorvência a 409 nm e a capacidade dos fármacos impedirem a oxidação proteica foi determinada 
pelo cálculo da área sob a curva da oxidação da mioglobina.  
Resultados e Conclusões: A fluvastatina (AUC50 = 12,5 ± 1,2 µM) e o enalapril (AUC50 = 15,2 
± 1,8 µM) foram os que demonstraram maior capacidade para impedir a peroxidação da 
mioglobina, que foi inclusivamente superior à de antioxidantes endógenos tais como a glutationa 
reduzida. O labetalol, enalapril e a fluvastatina previnem a auto-oxidação da mioglobina, enquanto 
a glutationa demonstrou um efeito pro-oxidante. 
Palavras-chave: Mioglobina; Radical peroxilo; Oxidação proteica; Microplaca; Estatinas; β-
Bloqueadores.  
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1. Introduction 
Redox reactions are characterized by chemical mechanisms that involve the oxidation (loss of 
electrons) of one substance and the reduction (acceptance of electrons) of another substance [1]. 
These reactions are essential for numerous biochemical pathways and cellular chemistry, 
biosynthesis and regulation of cell signaling [2]. In biological systems, pro-oxidant is a substance 
that undergoes reduction by inducing oxidative damage to various biological targets such as 
nucleic acids, lipids and proteins. On the other hand, an antioxidant is a substance that can 
efficiently counteract the activity of a pro-oxidant, reducing oxidation and inducing the 
concomitant formation of products having no or low toxicity. In 1995, Halliwell et al. [3] suggested 
that an antioxidant is “any substance that when present at low concentrations, compared to those 
of an oxidizable substrate significantly delays or prevents oxidation of that substrate”. In this 
context, not all reductants involved in a chemical reaction are antioxidants, only those compounds 
which are capable of protecting the biological target (oxidizable substrate). 
The pro-oxidants are referred as reactive oxygen species (ROS) such as alkoxyl radicals (RO•), 
peroxyl radicals (ROO•), hydroxyl radical (HO•), superoxide anion radical (O2
•–), singlet oxygen 
(1O2), hydrogen peroxide (H2O2) and hypochlorous acid (HOCl). Reactive nitrogen species (RNS) 
are also produced such as nitric oxide radical (NO•), nitrogen dioxide radical (NO2
•) and 
peroxynitrite anion (ONOO–) [4, 5]. These reactive species, can be easily formed from exposure 
of organisms to exogenous sources (UV-irradiation, drugs, pollutants, toxins, pesticides and 
herbicides) and much more important to endogenous sources that is a continuous process such as 
from mitochondrial electron-transport chain and from activity of some enzymes as nitric oxide 
synthases and xanthine oxidase [6]. Moreover, activated phagocytes produce a variety of reactive 
species that play an important role in the mechanism of defense against infectious agents [7].  
Depending on the site and the concentration generated, these reactive species are well recognized 
for playing a dual role, as both beneficial and deleterious effects have been established [8]. To 
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prevent the oxidative damage mediated by these species, living cells have developed a complex 
defense system composed of enzymatic (superoxide dismutase, catalase and glutathione 
peroxidase) and non-enzymatic antioxidants (uric acid, glutathione, bilirubin and albumin) that 
convert them to harmless species. Dietary antioxidants such as ascorbic acid (vitamin C), α-
tocopherol (vitamin E), carotenoids and polyphenolic compounds have also an important role in 
protecting essential biological targets against ROS/RNS action [4]. 
The state called ‘oxidative stress’ occurs when this balance can be shifted towards the pro-oxidant 
agents due to an overproduction of ROS/RNS and/or to a decrease of antioxidant protection [9]. 
This can be triggered by several factors such as genetic, diet, lifestyle, environmental conditions 
and diseases [6]. The oxidative stress has been implicated in the pathogenesis and development of 
several human diseases, including cardiovascular diseases [10], cancer [11], diabetes mellitus [12], 
inflammatory diseases [13], ischemia/reperfusion injury [14-16] and neurodegenerative disorders 
[17]. 
In this context, the interest in antioxidant research has become a topic of increasing attention in 
the last two decades, especially within biological, medical and nutritional fields. In the case of 
biological samples (e.g. plasma, serum, urine), measurement of antioxidant status may be helpful 
for diagnostic and treatment monitoring, especially during supplementation trials for boosting 
plasmatic antioxidant levels [18]. However, a validated in vitro assay that can reliably measure the 
total antioxidant capacity of biological samples is not yet available. This situation is due to the fact 
that the term total antioxidant capacity is a broader definition that covers: i) inhibition of generation 
and scavenging capacity against ROS/RNS; ii) reducing capacity; iii) metal chelating capacity; iv) 
activity of antioxidative enzymes; v) and inhibition of oxidative enzymes. Moreover, different 
antioxidants act by different mechanisms and even the same compound can have different ways 
of actuation [19]. For that reason, the evaluation of overall antioxidant capacity is complex and 
requires multiple assays to generate an “antioxidant profile” [20].  
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Drugs that scavenge reactive oxygen species (ROS) and/or inhibit the protein and lipid 
peroxidation have beneficial clinical effects in the prevention and/or treatment of oxidative-stress 
related diseases, usually named as pleotropic effects [21]. For instance, statins, namely 3-hydroxy-
3-methylglutaryl coenzyme A reductase (HMG-CoA reductase) inhibitors, are the first line therapy 
for lowering cholesterol levels but various cholesterol-independent beneficial properties, such as 
reduction of endothelial dysfunction, stabilization of atherosclerotic plaques and decrease of 
oxidative stress have been indicated, that may potentiate their clinical effects [22]. Actually, 
current therapeutic strategies are based on the design of multifunctional drug candidates that are 
able to interact with multiple disease related targets, with the advantages of reduced molecularity, 
absence of drug-drug interactions and improved pharmacokinetics and pharmacodynamics [23].  
The analytical methods that have been applied to measure the scavenging capacity of drugs are 
not adequate because the assays are based on the use of synthetic radical, such as 2,2-diphenyl-1-
picrylhydrazyl radical (DPPH•) and 2,2′-azinobis-(3-ethylbenzothiazoline-6-sulphonate) radical 
cation (ABTS•+) and/or on competitive assays that uses target molecules (e.g., fluorescein, luminol 
and pyrogallol in Oxygen Radical Absorbance Capacity, named as ORAC assay) that do not 
represent any reactive species and biotarget, respectively, found in living organisms [24]. 
The research work presented in this thesis was directed to the development of a novel analytical 
approach to determine the scavenging capacity of cardiovascular drugs using reactive species and 
oxidizable substrates found at biological milieu. Among the ROS formed in pathophysiological 
conditions, peroxyl radicals were selected as oxidizing species because they are responsible for 
the propagation step of lipid and protein peroxidation [8]. Hence, the peroxyl radicals generated 
from thermo-decomposition of 2,2´-azobis (2-methylpropionamidine) dihydrochloride (AAPH) 
and an endogenous protein (myoglobin) were used as models of reactive species and biotarget, 
respectively (Figure 1). 
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Figure 1. Schematic representation of myoglobin (Mb) oxidation mediated by peroxyl radicals (ROO•) generated 
from thermolysis of 2,2´-azobis (2-methylpropionamidine) dihydrochloride (AAPH) and its prevention by drugs. 
 
 
The myoglobin oxidation induced by peroxyl radicals was monitored by the absorbance decrease 
at 409 nm under reaction conditions (pH, temperature) similar to those found in vivo (Fig. 1). The 
analytical protocol was implemented in a microplate format in order to obtain a high-throughput 
procedure. The capacity of cardiovascular drugs and endogenous antioxidants to prevent protein 
oxidation was determined by the increase of the area under the curve (AUC) and the antioxidant 
effectiveness of drugs were characterized by their IC50 values, which represents the drug 
concentration that causes 50% inhibition of myoglobin oxidation. Finally, the scavenging capacity 
of several drugs, such as β-blockers (atenolol, labetalol, propanolol), statins (pravastatin, 
fluvastatin) and angiotensin-converting enzyme (ACE) inhibitors (enalapril) was compared to that 
obtained for endogenous antioxidants (reduced glutathione and taurine). 
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ROO •
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2. Objectives 
The main aims of the present work were: 
i) to develop a high-throughput microplate approach to determine the ROS scavenging 
capacity of drugs applying relevant biological reactive species (peroxyl radicals) and targets 
(myoglobin); 
ii) to monitor in a continuous mode the myoglobin peroxidation by the absorbance decrease at 
409 nm under reaction conditions (pH, temperature) similar to those found in vivo; 
iii) to determine the role of ethanol and DMSO used as cosolvents upon the oxidation kinetics 
of myoglobin;  
iv) to determine the prevention of autoxidation of myoglobin by cardiovascular drugs;  
v) to assess the capacity of drugs to prevent protein peroxidation by the increase of the area 
under the curve (AUC); 
vi) to compare the scavenging capacity of several drugs used for cardiovascular pathologies, 
such as several ACE inhibitors, β-blockers and statins with endogenous antioxidants.  
Finally, at the end of this work it is expected that the results obtained may elucidate the relevance 
of the antioxidant activity of some cardiovascular drugs as an additional pleiotropic effect. 
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4. General conclusions 
The analytical approach developed using biomimetic system represents a step forward for 
physiologically relevant antioxidant assays and for the assessment of ability of drugs to protect 
biotargets from oxidative damage. The microplate protocol allows monitoring in a continuous 
mode the myoglobin peroxidation providing kinetic information about the ability of drugs to 
prevent protein oxidation. Drugs with low solubility in buffer media could be tested at 10% (v/v) 
in ethanol with minor modifications in the heme environment of myoglobin, while dimethyl 
sulfoxide (DMSO) as cosolvent should be avoided. Moreover, for comparison purposes the 
antioxidant standard compound (Trolox) should also be tested under the same conditions. 
The autoxidation process of myoglobin, which is an important role in pathophysiology of 
vasospasms following subarachnoid hemorrhages and renal dysfunction after rhabdomyolisis, was 
inhibited to 2.5–5.0% by Trolox (100 µM), labetalol (100 µM), enalapril (100 µM) and fluvastatin 
(37.5 µM), while taurine (500 µM), atenolol (500 µM), propranolol (100 µM) and pravastatin (100 
µM) did not prevent autoxidation. On the other hand, for reduced glutathione a pro-oxidant effect 
was observed since the autoxidation of myoglobin increased up to 30% after 4h of reaction 
monitoring. This took place because the interaction of thiols with reactive radicals can generate 
thiyl radicals which have a pro-oxidant effect, especially in iron-rich environments, which is the 
case of iron atoms release during Mb autoxidation. 
Among the drugs tested, fluvastatin (12.5 ± 1.2 μM), enalapril (15.2 ± 1.8 μM) and propranolol 
(21.0 ± 2.2 μM) were those that presented higher ability to prevent myoglobin oxidative damage, 
even higher than that determined for reduced glutathione (232 ± 10 μM). These results indicate 
that these drugs may have pleiotropic effects by preventing oxidative damage of biomolecules, 
such as myoglobin. Finally, the proposed microplate protocol allowed the assessment of 
antioxidant capacity of two drugs in less than 4h, with control of different reaction conditions and 
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the estimated cost per analysis for each drug is about 0.90 €. And this is particularly important 
since health care costs is one of the most important challenges of our time. 
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Figure S1. Representation of the 96-well microplate scheme applied for monitoring of myoglobin oxidation from 
peroxyl radicals and its protection by drugs: AAPH, 100 μl of AAPH (180 mM) + 200 μl phosphate buffer (pH 7.4, 
50 mM,); Mb, 100 μl of myoglobin (75 μg/mL) + 200 μl of phosphate buffer; A6 or B6, 100 μl of the highest 
concentration of drug A or B + 200 μl phosphate buffer; AA6 or AB6, 100 μl of AAPH (180 mM) + 100 μl of the 
highest concentration of drug A or B + 100 μl phosphate buffer; MA6 or MB6, 100 μl of myoglobin (75 μg/mL) + 
100 μl of the highest concentration of drug A or B + 100 μl phosphate buffer; Ct, 100 μl of myoglobin (75 μg/mL) + 
100 μl of AAPH (180 mM) + 100 μl phosphate buffer; DAi, 100 μl of myoglobin (75 μg/ml) + 100 μl of AAPH (180 
mM) + 100 μl of drug A with increasing concentrations; DBi, 100 μl of myoglobin (75 μg/ml) + 100 μl of AAPH (180 
mM) + 100 μl of drug B with increasing concentrations. Each experiment was performed in quadruplicate and in three 
different days. 
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Figure S2. UV–Vis spectra of myoglobin solution (90 µg/mL) in the presence of AAPH solution (60 mM) obtained 
at different reaction times (0, 30, 60, 90 and 120 min). The absorbance peak (409 nm) of native myoglobin decrease 
throughout reaction time due to protein oxidation induced by peroxyl radicals. Intrinsic absorbance of AAPH was 
subtracted from the absorbance decay of myoglobin. 
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Figure S3. Molecular structures of cardiovascular drugs, endogenous antioxidants (glutathione and taurine) and 
standard antioxidant (Trolox) tested. 
Enalapril maleate salt 
Reduced glutathione
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